The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InPulmatrix, Inc. (Nasdaq: PULM) and Eos SENOLYTIX have announced a definitive merger agreement to create a combined biotechnology company focused on human healthspan. Following the acquisition of Eos by Pulmatrix, the new entity will operate under the name Eos SENOLYTIX. The strategic move aims to accelerate the development of mitochondrial therapies specifically designed to combat age-related diseases. To support these clinical efforts, the companies have secured $19 million in financing to advance their lead candidate, PTC-2105, for the treatment of sarcopenia. This merger combines specialized expertise in gerotherapeutic peptides to address significant unmet medical needs. Investors view the deal as a positive step for Pulmatrix, providing both the necessary capital and a clear clinical pathway in the high-growth biotech sector.